Pipeline

We prioritize disease areas with clear immune involvement, high unmet clinical need, and where EVs offer a best-in-class biological advantage over traditional biomarker approaches.

Discovery

Validation

Regulatory Approval

Discovery

Validation

Regulatory Approval

Discovery

Validation

Regulatory Approval

Melanoma

IO Therapeutics

Anti-PD-1 and Anti-PD-1 + anti-CTLA-4

124-patient discovery cohort, external prospective validation at three European centers.

Clinician examining a skin lesion with a dermatoscope.

Melanoma

IO Therapeutics

Anti-PD-1 and Anti-PD-1 + anti-CTLA-4

124-patient discovery cohort, external prospective validation at three European centers.

Melanoma

IO Therapeutics

Anti-PD-1 and Anti-PD-1 + anti-CTLA-4

124-patient discovery cohort, external prospective validation at three European centers.

Lung

IO Therapeutics

Anti-PD-(L)1 monotherapy and combinations

Paid pilot on archived clinical-trial samples in collaboration with a top-tier pharma partner.

Doctor listening to a patient’s back with a stethoscope.

Lung

IO Therapeutics

Anti-PD-(L)1 monotherapy and combinations

Paid pilot on archived clinical-trial samples in collaboration with a top-tier pharma partner.

Lung

IO Therapeutics

Anti-PD-(L)1 monotherapy and combinations

Pipeline

Melanoma

124-patient discovery cohort, external prospective validation at three European centers.

Melanoma

124-patient discovery cohort, external prospective validation at three European centers.

Melanoma

124-patient discovery cohort, external prospective validation at three European centers.

Lung

Paid pilot on archived clinical-trial samples in collaboration with a top-tier pharma partner.

Lung

Paid pilot on archived clinical-trial samples in collaboration with a top-tier pharma partner.

Lung

Paid pilot on archived clinical-trial samples in collaboration with a top-tier pharma partner.

Clinical Partners

Clinical Partners

Clinical Partners